title: Checkmate: kidney injury associated with targeted cancer immunotherapy.
abstract: Immune checkpoint inhibitors are a class of drugs that utilizes immunotherapy to target various cancers. Included are the anti-CTLA-4 and anti-PD-1 receptor antibodies. By reprogramming the immune system, these agents provide a therapy that destroys cancer cells. However, this approach runs the risk of allowing pathologic autoimmunity and organ injury to develop. Unsurprisingly, immune-related adverse effects are described including pneumonitis, colitis, and various endocrinopathies. Now added to this list is AKI, primarily due to ATIN.
authors: Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Section of Nephrology, Department of Medicine, VA Medical Center, West Haven, Connecticut, USA. Electronic address: Mark.perazella@yale.edu.
authors: Mark A
authors: MA
authors: Perazella
mesh_terms: D059447:Cell Cycle Checkpoints / Q000276:immunology; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*
chemical_list: D061026:Programmed Cell Death 1 Receptor